Form 4: Immuneering Corp Executive Granted Stock Options

Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp, was granted stock options for 110,000 shares on February 5, 2025.

Summary

• Michael Bookman, the Chief Legal Officer and Secretary of Immuneering Corp, received stock options.
• The transaction occurred on February 5, 2025.
• The stock options are for 110,000 shares of Class A Common Stock.
• The exercise price of the options is $1.91.
• The options vest in equal monthly installments over four years, starting February 1, 2025, and will be fully vested by January 1, 2029.
• The options expire on February 5, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for executive compensation.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant is typical for a company of Immuneering Corp's size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options extensively to incentivize their leadership teams.
• The vesting schedule of four years is also typical, aligning with industry norms for long-term retention.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive long-term value.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates